Evidence map›Paper›PMID 29912986›Full record

ArticlePLoS pathogens2018

A recombinant herpesviral vector containing a near-full-length SIVmac239 genome produces SIV particles and elicits immune responses to all nine SIV gene products.

Young C Shin, Georg F Bischof, William A Lauer, Lucas Gonzalez-Nieto, Eva G Rakasz, Gregory M Hendricks, David I Watkins, Mauricio A Martins, Ronald C Desrosiers

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Vaccine protection against SIVmac239 acquisition.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Young C ShinDepartment of Pathology, Miller School of Medicine, University of Miami, Miami, Florida, United States of America.
Georg F BischofDepartment of Pathology, Miller School of Medicine, University of Miami, Miami, Florida, United States of America.ORCID 0000-0002-0179-0046
William A LauerDepartment of Pathology, Miller School of Medicine, University of Miami, Miami, Florida, United States of America.ORCID 0000-0002-1580-9721
Lucas Gonzalez-NietoDepartment of Pathology, Miller School of Medicine, University of Miami, Miami, Florida, United States of America.
Eva G RakaszWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.ORCID 0000-0001-8197-5309
Gregory M HendricksDepartment of Cell and Developmental Biology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
David I WatkinsDepartment of Pathology, Miller School of Medicine, University of Miami, Miami, Florida, United States of America.
Mauricio A MartinsDepartment of Pathology, Miller School of Medicine, University of Miami, Miami, Florida, United States of America.ORCID 0000-0001-8336-216X
Ronald C DesrosiersDepartment of Pathology, Miller School of Medicine, University of Miami, Miami, Florida, United States of America.
University of Miami · USUniversity of Massachusetts Chan Medical School · USUniversity of Wisconsin–Madison · US

Funding

WNPRC Supplemental Request for Nonhuman Primate Enclosures to Equip HIV/AIDS-Related Research FacilitiesP51OD011106 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI Dorota A. Grejner-Brzezinska · 2012 to 2026
$150.7M
University of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI ALLAN E RODRIGUEZ · 2007 to 2026
$33.8M
Yellow Fever Vector Development P01AI094420 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BONALDO, MYRNA C · 2012 to 2016
$11.4M
The Functional Significance of CTL EscapeR37AI052056 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI WATKINS, DAVID I · 2008 to 2017
$7.1M
Gamma-2 Herpesviruses as Vaccine Vectors for AIDSR37AI063928 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI DESROSIERS, RONALD C · 2013 to 2022
$5.1M
Can vaccine-induced CD8 T cells prevent chronic phase AIDS virus replication?R01AI108421 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI WATKINS, DAVID I · 2014 to 2018
$2.9M
Ipilimumab as an adjuvant for HIV vaccinesK01OD023032 · OD · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI MARTINS, MAURICIO DE AGUIAR · 2016 to 2018
$993k
UltramicrotomeS10OD021580 · OD · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI HENDRICKS, GREGORY · 2016 to 2016
$53k
NIAID NIH HHS P01 AI094420NIAID NIH HHS P30 AI073961NIAID NIH HHS R01 AI108421NIAID NIH HHS R37 AI052056NIAID NIH HHS R37 AI063928NIH HHS K01 OD023032NIH HHS P51 OD011106NIH HHS S10 OD021580
6 · The paper itself

Abstract

The properties of the human immunodeficiency virus (HIV) pose serious difficulties for the development of an effective prophylactic vaccine. Here we describe the construction and characterization of recombinant (r), replication-competent forms of rhesus monkey rhadinovirus (RRV), a gamma-2 herpesvirus, containing a near-full-length (nfl) genome of the simian immunodeficiency virus (SIV). A 306-nucleotide deletion in the pol gene rendered this nfl genome replication-incompetent as a consequence of deletion of the active site of the essential reverse transcriptase enzyme. Three variations were constructed to drive expression of the SIV proteins: one with SIV's own promoter region, one with a cytomegalovirus (cmv) immediate-early promoter/enhancer region, and one with an RRV dual promoter (p26 plus PAN). Following infection of rhesus fibroblasts in culture with these rRRV vectors, synthesis of the early protein Nef and the late structural proteins Gag and Env could be demonstrated. Expression levels of the SIV proteins were highest with the rRRV-SIVcmv-nfl construct. Electron microscopic examination of rhesus fibroblasts infected with rRRV-SIVcmv-nfl revealed numerous budding and mature SIV particles and these infected cells released impressive levels of p27 Gag protein (>150 ng/ml) into the cell-free supernatant. The released SIV particles were shown to be incompetent for replication. Monkeys inoculated with rRRV-SIVcmv-nfl became persistently infected, made readily-detectable antibodies against SIV, and developed T-cell responses against all nine SIV gene products. Thus, rRRV expressing a near-full-length SIV genome mimics live-attenuated strains of SIV in several important respects: the infection is persistent; >95% of the SIV proteome is naturally expressed; SIV particles are formed; and CD8+ T-cell responses are maintained indefinitely in an effector-differentiated state. Although the magnitude of anti-SIV immune responses in monkeys infected with rRRV-SIVcmv-nfl falls short of what is seen with live-attenuated SIV infection, further experimentation seems warranted.

Indexed as

AnimalsGammaherpesvirinaeGenetic VectorsGenome, ViralHerpesviridae InfectionsHumansImmunity, CellularMacaca mulattaSimian Immunodeficiency VirusViral ProteinsVirionViral Proteins

Identifiers

PMID29912986
PMCPMC6023237
OpenAlexW2809590394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.